BDBM622512 US20230312583, Compound I-8

SMILES CCOc1cc(Nc2ncc3ccc4ncn(C(C)C)c4c3n2)ncc1N1CCOCC1

InChI Key InChIKey=GYIJQQCWXZLRDA-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 622512   

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 0.0310nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 2.95nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 89.1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622512(US20230312583, Compound I-8)
Affinity DataIC50: 500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent